COVID mutation, slow vaccine production may return to normal life at a slow pace: Biden

President Biden said on Friday that life could not return to normal in 2021 due to COVID-19 mutations and potential disruptions in US vaccine production.

Biden said at a Pfizer vaccine factory in Mrs. Portage that mutations of the virus and unexpected vaccine production blips could lead to the social and economic collapse of the epidemic.

“I believe we’ll be back to normal by the end of this year. God willing, this Christmas will be different than the last. But I can’t make that commitment to you. There are other strains of the virus. We don’t know if the production rates. In terms of what can happen. Things can change, “said Biden.

The chairman spoke about life amid widespread optimism, which is returning to normal due to the rate of infection and vulnerable groups of people being vaccinated.

He said a snowstorm this week delayed the shipment of some vaccines.

Biden said in Michigan, meanwhile, “I think it’s important to get our kids back to school.” He has faced criticism for not putting more pressure on reluctant teacher unions to do so.

President Joe Biden speaks after a visit to the Pfizer construction site on Friday, February 19, 2021, in Portfez, Mich.
President Joe Biden speaks on February 19, 2021, after visiting a Pfizer construction site in Portage, Michigan.
AP Photo / Ivan Vukie

According to Bloomberg News Analysis of public data, The US has injected more than 59 million vaccine doses – or 17.8 doses per 100 people.

Two US approved vaccines from Pfizer-BioNTech and Moderna, require two shots, but are 95 percent and 94.1 percent effective. The two vaccines are being given to people at a rate of 1.58 million doses per day, which should allow the US to secure herd immunity this summer.

The single-shot vaccine produced by Johnson & Johnson, which is at least 66 percent effective, is expected to further intensify the vaccination deadline when approved by the Food and Drug Administration earlier this month.

Preliminary research indicates that vaccines are less effective against emerging and more infectious COVID-19 variations.

For example, the Johnson & Johnson vaccine is 66 percent effective worldwide, but 72 percent effective in the US, where there is a low prevalence of mutations in the UK, Brazil and South Africa.

Novax has a different vaccine in development. 60 percent Effective in South Africa. In the UK, the same vaccine was 95.6 percent effective against the original variant and 85.6 percent effective against the UK variant.

Biden’s chief medical advisor, Dr. Anthony Fauci said on Friday that the new changes to the virus meant that the government and companies would “have to be agile to easily accommodate versions of the vaccine specifically directed to the circulation of mutations.”

Be the first to comment

Leave a Reply

Your email address will not be published.